Lancet neurology
-
Comment Letter
Unanswered questions from the Evoke trial - Author's reply.
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder. ⋯ Chugai Pharmaceutical (Roche).